menu
    • menu

    Company profile for BerGenBio ASA

    NEW Drugs in Dev: 5
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. AXL signalling plays a crucial role both in tumour cells where it promotes immune evasion, drug resistance and cancer spread, and in immune cells where it suppresses tumour recognition and cell-killing. Therefo...
    BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. AXL signalling plays a crucial role both in tumour cells where it promotes immune evasion, drug resistance and cancer spread, and in immune cells where it suppresses tumour recognition and cell-killing. Therefore, blocking AXL activity represents a novel approach to prevent cancer survival mechanisms and to improve the efficacy of chemotherapy, targeted therapy and immuno-oncology drugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    BerGenBio ASANorway Flag
    Country
    Country
    Norway
    Address
    Address
    Jonas Lies vei 91 5009 Bergen
    Telephone
    Telephone
    + 47 559 61 159
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bergenbio.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/bergenbio-as
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/bgenbio?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ber Gen Bio and Oncoinvent Propose Merger and Rights Issue
    Ber Gen Bio and Oncoinvent Propose Merger and Rights Issue

    30 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-and-oncoinvent-a-rising-innovator-in-radiopharmaceutical-cancer-therapies-announce-proposed-merger-and-a-fully-underwritten-rights-issue-302494915.html

    PR NEWSWIRE
    30 Jun 2025
    Share Share
    BerGenBio Enrolls 1st Patient In Adenocarcinoma Lung Cancer Trial
    BerGenBio Enrolls 1st Patient In Adenocarcinoma Lung Cancer Trial

    07 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-first-patient-entered-into-advanced-adenocarcinoma-lung-cancer-trial-302343901.html

    PR NEWSWIRE
    07 Jan 2025
    Share Share
    BerGenBio Appoints Olav Hellebø as CEO
    BerGenBio Appoints Olav Hellebø as CEO

    20 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-appoints-olav-hellebo-as-ceo-302312066.html

    PR NEWSWIRE
    20 Nov 2024
    Share Share
    BerGenBio Q3 Results 2024
    BerGenBio Q3 Results 2024

    13 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-third-quarter-results-2024-302303714.html

    PR NEWSWIRE
    13 Nov 2024
    Share Share
    BerGenBio Announces Safety Data From Phase 1b In NSCLC Patients
    BerGenBio Announces Safety Data From Phase 1b In NSCLC Patients

    07 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-safety-data-from-dose-escalation-phase-1b-in-first-line-nsclc-patients-302268551.html

    PR NEWSWIRE
    07 Oct 2024
    Share Share
    BerGenBio Announces Phase 1b Safety Data for NSCLC Patients
    BerGenBio Announces Phase 1b Safety Data for NSCLC Patients

    07 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bergenbio-announces-safety-data-from-dose-escalation-phase-1b-in-first-line-nsclc-patients-302268547.html

    PR NEWSWIRE
    07 Oct 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search